Aug 2026· Antimicrobial Agents and Chemotherapy· Vol 70· 0 citations· 54 references
Medicine
TL;DR
5-fluorouridine is identified as a promising antifungal candidate and C-5-halogenated nucleosides are established as a privileged scaffold for antifungal drug development.
Abstract
ABSTRACT The emergence of multidrug-resistant Candidozyma auris has created an urgent need for antifungals with novel mechanisms of action. We screened 121 nucleoside and nucleobase derivatives against C. auris and other clinically relevant Candida species to identify effective antimetabolite scaffolds. Among all compounds tested, only the C-5-fluorinated nucleosides 5-fluorouridine (5-FU) and 5-fluorocytidine exhibited potent antifungal activity. 5-FU demonstrated consistently low minimum inhibitory concentrations (0.5–10 µg/mL) across multiple Candida species, including fluconazole-resistant strains, and displayed fungicidal activity against C. auris at concentrations lower than several frontline antifungals. Uridine rescue assays confirmed competitive interference with endogenous uridine metabolism. Checkerboard assays revealed synergistic or additive interactions between 5-FU and clinically used azoles and echinocandins. Toxicity evaluation using plant, nematode, and human cell models showed minimal cytotoxicity even at concentrations far exceeding antifungal minimum inhibitory concentrations. In silico docking analyses revealed dual inhibition of thymidylate synthase and RNA polymerase III, explaining the fungicidal phenotype and broad-spectrum efficacy. These findings identify 5-fluorouridine as a promising antifungal candidate and establish C-5-halogenated nucleosides as a privileged scaffold for antifungal drug development.
The combined antifungal, antibiofilm, mechanistic, structural, and computational findings identify compound 3d as the most promising, highlighting indole-thiosemicarbazides as a valuable scaffold for ergosterol-targeted antifungals effective against drug-sensitive and resistant Candida.
Compound F4 emerges as a promising lead for antifungal drug development, distinguished by its broad‑spectrum activity, antibiofilm properties, and unique capacity to eliminate FLC tolerance.
Jia-Yin Wang, Qin-Li Guo, Nan Chen et al.· Drug Design, Development and...· 0 citations
D dehydronuciferine is identified as a promising antifungal chemosensitizer that enhances fluconazole efficacy against drug-resistant C. albicans through multitarget perturbation of resistance- and virulence-associated processes.
Xiu-Yun Li, Ai Zhang, Tajiguli Kupi et al.· Microbiology spectrum· 0 citations
Systematic variation of linker architecture identified compound 28 as a promising exploratory antifungal lead, exhibiting sub-microgram MIC values against several Candida isolates, and retaining measurable activity against an azole-resistant C. albicans strain.
A. Y. Rudenko, Olga A Komarova, A. Y. Simonov et al.· Pharmaceuticals· 0 citations
SSD2032594 showed a survival benefit in the Caenorhabditis elegans nematode model of C. auris infection, resulting in a ∼30% higher survival rate, and is highlighted as a candidate for antifungal drug development, targeting infections caused by different fungal pathogens.
Matthew P. Dupuis, Nour M. Alkashef, Roman A. Matamoros et al.· Journal of Medicinal Chemist...· 0 citations
Mechanistic investigations demonstrated that compound 7b markedly disrupted fungal sterol biosynthesis, as evidenced by significant ergosterol depletion, lanosterol accumulation, and a pronounced reduction in the ergosterol/lanosterol ratio across all tested Candida species.
R. Hendra, Rahmad Setiawan Rabby, Tengku Anggia Fitri et al.· Medicinal Chemistry Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.